Drug intelligence / Profile preview

AMX0318

Development stage: Preclinical
Lead developer: Amylyx Pharmaceuticals
Modality: Peptides

Overview

AMX0318 is a long-acting peptide designed as a glucagon-like peptide 1 (GLP-1) receptor antagonist. Developed by Amylyx Pharmaceuticals in collaboration with Gubra, it is being investigated for the treatment of post-bariatric hypoglycemia (PBH) and other rare endocrine/metabolic diseases. The drug candidate was identified using Gubra's AI-driven "streaMLine" peptide discovery platform.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on AMX0318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMX0318.

Explore the full profile